Breakthrough for advanced head and neck cancer patients as nivolumab made available on the Cancer Drugs Fund

The immunotherapy nivolumab has today been made available on the Cancer Drugs Fund (CDF) for patients with head and neck cancer if the disease progresses within six months of receiving platinum chemotherapy.
Institute of Cancer Research